Neuvotion develops NeuStim™, a technology that combines highly targeted neurostimulation with artificial intelligence to accelerate rehabilitation and make physical and occupational therapy more effective. The company focuses on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Neuvotion plans a multi-site clinical study to begin this year and intends to complete clinical studies using the new funding. Management says it will use the funds to expand its team and pursue FDA clearance for its initial product. Founded by Chad Bouton and based in Darien, CT, Neuvotion is in the early-stage clinical and regulatory phase. The company recently raised additional capital that brings its total funding to $2.75M. Neuvotion is an early-stage medical device company focused on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Its core product, NeuStim™, combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. The company is led by founder and CEO Chad Bouton and is based in Darien, CT. Neuvotion has received an exclusive worldwide license from Northwell Health for its technology. It raised over $1M in seed funding to advance development and clinical validation, and plans to use the proceeds to expand its team, conduct a multi-site clinical study next year, and pursue FDA clearance for its initial product.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2023